Harvard professor Will Mair's aging research lab faces collapse after federal funding cuts triggered by the university's refusal to comply with Trump administration demands. The White House terminated billions in research grants, including over $1 million promised to Mair's team studying how to help people age better.

Mair, 47, had been building an interdisciplinary Center for Healthy Aging, which he called an 'aging moonshot' modeled after Kennedy's moon mission. His team's work on breakthrough drugs like Ozempic and Wegovy emerged from decades of costly, uncertain research that no for-profit company could sustain. 'No for-profit company could possibly withstand all the false leads,' Mair explained to an audience after learning of the cuts mid-presentation.

Rather than lay off staff, Mair used his tenure-negotiated rainy day fund to keep his team together, telling them 'no one is coming to save us.' The Chan School of Public Health, where Mair works, faces particular vulnerability with 40% of revenue from federal sources. Mair now must reinvent his funding model while weighing whether to stay at Harvard or move to a less-targeted institution, all while maintaining his decade-long research momentum.